STOCK TITAN

Opko Health Stock Price, News & Analysis

OPK Nasdaq

Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.

OPKO Health Inc (OPK) maintains this comprehensive news hub for investors and healthcare professionals tracking developments in precision diagnostics and therapeutic innovation. Our curated collection features official press releases, regulatory filings, and verified third-party analysis of OPKO's advancements in genetic testing platforms and pharmaceutical research.

This resource serves as a centralized repository for monitoring strategic initiatives across OPKO's core segments: clinical diagnostics through BioReference Health laboratories, and pharmaceutical development targeting metabolic disorders and chronic conditions. Users will find updates on clinical trial progress, partnership announcements, and operational milestones within the company's global supply network.

Key content categories include earnings reports, product pipeline developments, FDA regulatory updates, and strategic business decisions. The page is regularly updated to reflect OPKO's evolving position in healthcare markets while maintaining historical context for longitudinal analysis.

Bookmark this page or set news alerts to stay informed about OPKO Health's contributions to diagnostic technology and targeted therapies. For verified information directly from corporate sources, we recommend cross-referencing filings with official SEC documentation.

Rhea-AI Summary

OPKO Health, Inc. (OPK) reported a net income of $32.3 million for Q4 2020, a significant recovery from a net loss of $112.4 million in the prior year. Consolidated revenues surged to $494.6 million, driven by a 170% increase in BioReference Laboratories' volume, mainly due to COVID-19 PCR testing. However, revenues from pharmaceutical products, specifically Rayaldee, decreased to $30.8 million as new patient onboarding faced challenges. The company has $72.2 million in cash and equivalents, alongside available credit facilities totaling $157.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.26%
Tags
-
Rhea-AI Summary

OPKO Health, Inc. (NASDAQ: OPK) will report its financial results for Q4 2020 on February 18, 2021, after U.S. market close. The company will provide insights into its operational performance and future guidance during a conference call at 4:30 p.m. Eastern Time on the same day. Interested individuals can pre-register for the call or listen via a live audio webcast. A replay will be available post-call on OPKO's website, ensuring stakeholders have access to the financial update and discussions on its strategic direction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences earnings
-
Rhea-AI Summary

OPKO Health, Inc. (NASDAQ: OPK) announced that Pfizer Japan submitted a New Drug Application for somatrogon, a long-acting recombinant human growth hormone intended for pediatric growth hormone deficiency treatment. This submission is based on Phase 3 studies showing somatrogon is as effective as GENOTROPIN (somatropin) in annual height velocity with comparable safety profiles. OPKO is responsible for the clinical program, while Pfizer handles registration and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
Rhea-AI Summary

GeneDx, a subsidiary of OPKO Health (NASDAQ:OPK), has launched new genetic tests, including repeat expansion analysis for spinocerebellar ataxia (SCA) and Friedreich ataxia. These tests aim to address the diagnostic challenges associated with hereditary ataxias, which often have genetic underpinnings. With a comprehensive offering, GeneDx enhances access to testing, overcoming the limitations of existing diagnostic laboratories. The expansion reflects the company's commitment to rare diseases and aims to provide more options for patients, thereby facilitating precise medical management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
-
Rhea-AI Summary

BioReference Laboratories, a subsidiary of OPKO Health, has signed agreements to provide COVID-19 testing for officials, players, and staff during the 2020-2021 seasons of the NBA and NHL. This includes PCR and rapid diagnostics across 30 NBA facilities in 28 U.S. cities. Additionally, BioReference supports U.S. Soccer's national teams and the Winter X Games. Executive Chairman Jon R. Cohen emphasized the company’s dedication to developing customized testing solutions. BioReference operates 11 lab locations and has a strong position in various healthcare segments, backing its testing services with a team of over 120 professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
covid-19
-
Rhea-AI Summary

BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has launched Scarlet Health, a digital platform for at-home diagnostic services. This innovative service allows patients to schedule specimen collection at their preferred locations, enhancing convenience and efficiency. Scarlet leverages BioReference's nationwide infrastructure, offering a secure and user-friendly experience for both patients and healthcare providers. As telemedicine investment surged to $1.6 billion in the past year, Scarlet aims to bridge the gap between traditional healthcare and modern telehealth services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
Rhea-AI Summary

OPKO Health (NASDAQ: OPK) will participate in the virtual 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. Management plans to host one-on-one meetings with investors and will present on January 13 at 3:40 p.m. Eastern time. The presentation will be available for live streaming and later replay in the Investors section of OPKO's website. This conference allows OPKO to showcase its strategies and innovations in the biopharmaceutical and diagnostics sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
-
Rhea-AI Summary

BioReference Laboratories, part of OPKO Health (NASDAQ: OPK), announced COVID-19 PCR test results for New York City's public schools, revealing a positivity rate of 0.47%. Testing began on September 2, 2020, with over 209,790 individuals tested across 1,200 schools, achieving an average turnaround time of 38 hours. The positivity rates varied by borough, with the Bronx having the highest at 0.71%. This initiative aims to ensure safe learning environments for students and staff amidst the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
covid-19
-
Rhea-AI Summary

Pfizer (PFE) and OPKO Health (OPK) announced that the FDA has accepted the filing of the Biologics License Application (BLA) for somatrogon, a long-acting growth hormone for treating pediatric growth hormone deficiency (GHD). The FDA's target decision date is in October 2021. Results from a Phase 3 trial demonstrated somatrogon met primary endpoints, showing higher annual height velocity compared to daily somatropin. The therapy offers potential benefits by reducing the need for daily injections. Somatrogon has received Orphan Drug designation in the U.S. and EU.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
Rhea-AI Summary

The Buffalo Bills, 2020 AFC East Division Champions, in partnership with BioReference Laboratories, an OPKO Health company (NASDAQ:OPK), announced a fan testing initiative for their upcoming AFC Divisional Wild Card playoff game. Fans must obtain a negative COVID-19 PCR test result within 72 hours to attend. The test scheduling will be facilitated through a URL provided to ticket purchasers. This initiative aims to ensure a safe environment and marks an innovative step in safely welcoming fans back to live sporting events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
covid-19

FAQ

What is the current stock price of Opko Health (OPK)?

The current stock price of Opko Health (OPK) is $1.28 as of July 31, 2025.

What is the market cap of Opko Health (OPK)?

The market cap of Opko Health (OPK) is approximately 1.1B.
Opko Health

Nasdaq:OPK

OPK Rankings

OPK Stock Data

1.07B
421.79M
59.26%
29.91%
13.32%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States
MIAMI